MSQ Ventures

@MsqVentures

A NY-based cross-border advisory firm that bridges healthcare and technology industries globally by offering deep knowledge and local insight of China’s market.

New York, NY
Vrijeme pridruživanja: veljača 2018.

Tweetovi

Blokirali ste korisnika/cu @MsqVentures

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MsqVentures

  1. 10. srp 2019.

    Ocumension ( ) focuses on , which rights to a for acute from France’s Nicox for $13.5M and sales milestones of $11.3M. NCX4251-US trial was from Nicox.

    Poništi
  2. 21. lip 2019.

    Thanks to everyone who attended the . Especially thanks to to co-host the morning discussion. Thanks for , , TECLens, and PainQx to our afternoon Roadshow session

    Poništi
  3. 13. lip 2019.

    will host a on June 20th at 750 Lexington Ave. The event brings together healthcare and western companies to generate synergy which will fuel this with partnership and .

    Poništi
  4. 11. lip 2019.

    Thanks to , , Founder & CEO at MSQ Ventures is invited to participate in the panel discussion “ Today in Tomorrow’s Life- - Opportunities for to Move to ”.

    Poništi
  5. 7. lip 2019.

    Thanks to for hosting Conference. joined “US-China Bilateral Investment” panel to discuss how to list the business overseas, and environment in , where sector is thriving.

    Poništi
  6. 3. lip 2019.

    Echo Hindle-Yang, CEO at MSQ Ventures, participated as the special guest in the China-US Partnering & Investment Panel, . Generated a wonderful discussion with companies and .

    Poništi
  7. 3. lip 2019.

    Dr. Mike Zhao, VP at MSQ Ventures just presented at Forum, Chicago. A variety of great questions and in-depth discussions occurred!

    Poništi
  8. 21. svi 2019.

    It's traveling time! Our CEO, Echo Hindle-Yang was invited to the 14th Annual World Advanced Therapies & Regenerative Medicine Congress and she joined a panel to discuss current opportunities and limitations in gene therapy.

    Poništi
  9. 15. svi 2019.

    Thank you to our special company presenters Christian Cortis, David Liebowitz, Hao Wang, Sam Goldberg, and Arif Khan for their deep understanding on blockchain applications in BioTech, Internet, FinTech, Digital Advertising, STO and AI sectors.

    Poništi
  10. 15. svi 2019.

    Thank you to our special panelists , , and for their insightful contributions discussing fundamental investment strategies, valuation methodology, business models, outlook, investible ideas and innovation.

    Poništi
  11. 15. svi 2019.

    Thanks for coming to our Blockchain Summit! We hope our audience enjoyed the relevant and material discussions on regulation, token/ STO/ equity structures, digital asset framework w/ , , IBM's David Post, Jay Liang and .

    Poništi
  12. 9. svi 2019.

    We are glad to announce an excellent blockchain summit co-hosted by and on May 13th, 2019 at 230 Park Avenue, New York. More information available: .

    Poništi
  13. 7. svi 2019.

    It's our great pleasure to have Andrea on our event. Thanks in advance for his great contribution!

    Poništi
  14. 6. svi 2019.

    Cstone will exclusively develop and commercialize ND021 in Greater China, South Korea, and Singapore in exchange of funding the R&D expense of ND021 till the completion of Phase 1b clinical trial.

    Poništi
  15. 6. svi 2019.

    Cstone Pharmaceuticals (China) -focus on the development and commercialization of innovative immuno-oncology/precision medicine, acquired the exclusive rights to Numab(Swiss)’s ND021, a tri-specific antibody which targets PD-L1, 4-1BB, and HSA.

    Poništi
  16. 3. svi 2019.

    4/29, Luye Pharma in-licensed China rights to PharmaMar’s lurbinectedin (Zepsyre®). The drug is under a phase 3 clinical study in combination with doxorubicin to treat Small Cell Lung Cancer, and it was granted orphan drug designation from FDA.

    Poništi
  17. 2. svi 2019.

    BRAVO!! Happy Anniversary to MSQ!! Thanks and for the hard work! Can’t wait for another year’s achievement! – mjesto: 110 Wall Street

    Korisnici , i
    Poništi
  18. 2. svi 2019.

    Viva Biotech(CRO) provides structure-based drug discovery services to pharmas and biotechs to support pre-clinical drug development, filed a Hongkong IPO to raise between $150-194M. Sinopharma Capital and GTJA Investment Group subscribed for 26% of Viva's offering.

    Poništi
  19. 12. tra 2019.

    BeiGene in-licensed a CTLA-4 inhibitor from BioAtla of San Diego in a $269 million agreement. The two companies will test BA3071 (CAB-CTLA-4) as a monotherapy and in combination with BeiGene's PD-1 candidate, tislelizumab.

    Poništi
  20. 3. tra 2019.

    Sichuan Haisco will invest $6 M in eXithera, a US Biopharma invested by Israel's Clal Biotechnology Industries. After the deal, Haisco will own 12.5% stake of eXithera and own China rights to a novel anticoagulant.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·